These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15377746)

  • 21. Psychotic depression: a peculiar presentation for multiple sclerosis.
    Agan K; Gunal DI; Afsar N; Tuncer N; Kuscu K
    Int J Neurosci; 2009; 119(11):2124-30. PubMed ID: 19863266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV; Kuzenkova LM; Maslova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks.
    Albert R; Ebert D
    J Clin Psychiatry; 1996 Apr; 57(4):176. PubMed ID: 8601556
    [No Abstract]   [Full Text] [Related]  

  • 24. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine.
    Uzunova V; Sheline Y; Davis JM; Rasmusson A; Uzunov DP; Costa E; Guidotti A
    Proc Natl Acad Sci U S A; 1998 Mar; 95(6):3239-44. PubMed ID: 9501247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible predictors of response to fluvoxamine for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Apr; 18(3):197-200. PubMed ID: 12672171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
    Alsalameh S; Manger B; Kern P; Kalden J
    Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494
    [No Abstract]   [Full Text] [Related]  

  • 27. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
    Ueda N; Yoshimura R; Shinkai K; Nakamura J
    Pharmacopsychiatry; 2002 Sep; 35(5):175-81. PubMed ID: 12237788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Okumura T; Tsunoka T; Ozaki N; Iwata N
    Neuromolecular Med; 2009; 11(2):53-7. PubMed ID: 19347611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Certain problems of therapy with beta-interferon preparations].
    Gusev EI; Demina TL; Boĭko AN; Khachanova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):98-102. PubMed ID: 12938643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis].
    Zimmermann C; Walther EU; Goebels N; Lienert C; Kappos L; Hartung HP; Hohlfeld R
    Nervenarzt; 1999 Aug; 70(8):759-63. PubMed ID: 10483579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Risk of affective disorder in multiple sclerosis].
    Stenager EN; Stage KB; Stenager E
    Ugeskr Laeger; 2011 Jan; 173(2):123-6. PubMed ID: 21219844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon beta-1b and childhood multiple sclerosis.
    Adams AB; Tyor WR; Holden KR
    Pediatr Neurol; 1999 Jul; 21(1):481-3. PubMed ID: 10428435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential disease-modifying effects of selective serotonin reuptake inhibitors in multiple sclerosis: systematic review and meta-analysis.
    Foley P; Lawler A; Chandran S; Mead G
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):709-10. PubMed ID: 24403283
    [No Abstract]   [Full Text] [Related]  

  • 35. [Double depression].
    Kaji K; Yoshimura R; Nakamura J
    Ryoikibetsu Shokogun Shirizu; 2003; (38):328-33. PubMed ID: 12876995
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
    Zettl UK; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Limmroth V;
    BMC Neurol; 2013 Sep; 13():117. PubMed ID: 24011220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
    Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
    J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients.
    Saito S; Takahashi N; Ishihara R; Ikeda M; Suzuki T; Kitajima T; Yamanouchi Y; Iwata N; Yamada M; Yoshida K; Inada T; Ozaki N
    Neuropsychobiology; 2006; 54(4):226-30. PubMed ID: 17356306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
    Sheline Y; Bardgett ME; Csernansky JG
    J Clin Psychopharmacol; 1997 Feb; 17(1):11-4. PubMed ID: 9004051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of amino acids in the treatment of major depression with fluvoxamine.
    Mauri MC; Boscati L; Volonteri LS; Scalvini ME; Steinhilber CP; Laini V; Zamberlan F
    Neuropsychobiology; 2001; 44(3):134-8. PubMed ID: 11586053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.